SCHEMBL1481209

SCHEMBL1481209

COC(=O)CCCOc1ccc(-c2ccc(/C=C/c3nc(-c4ccc(Cl)cc4Cl)cn3C)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
PTGS2 P35354 1/20 0.42
PDE3B Q13370 6/20 0.39
PDE3A Q14432 6/20 0.39
P2RY12 Q9H244 5/20 0.39
PDE2A O00408 2/20 0.39
CNR1 P21554 3/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
PABPC1 P11940 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
PPARA Q07869 1/20 0.37
KCNA3 P22001 1/20 0.37
HDAC3 O15379 1/20 0.36
STAT3 P40763 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481210 1.00 MAPT (0.44) MAPTPTGS2PDE3BPDE3AP2RY12
SCHEMBL1481647 0.97 PTGS2 (0.41) MAPTPTGS2PDE3BPDE3AP2RY12
SCHEMBL1481649 0.97 PTGS2 (0.41) MAPTPTGS2PDE3BPDE3AP2RY12
SCHEMBL1480591 0.91 FFAR4 (0.43) PDE3BPDE3AP2RY12CNR1PPARA
SCHEMBL1480594 0.91 FFAR4 (0.43) PDE3BPDE3AP2RY12CNR1PPARA
SCHEMBL1481219 0.90 MAPT (0.42) MAPTPTGS2PDE3BPDE3AP2RY12
SCHEMBL1481218 0.90 MAPT (0.42) MAPTPTGS2PDE3BPDE3AP2RY12
SCHEMBL1480586 0.89 PPARA (0.46) PDE3BPDE3APDE2ACNR1PPARA
SCHEMBL1480587 0.89 PPARA (0.46) PDE3BPDE3APDE2ACNR1PPARA
SCHEMBL6532509 0.87 MAPT (0.40) MAPTPTGS2PDE3BPDE3AP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885PTGS2 1093/4885PDE3B 183/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885PTGS2 1093/4885PDE3B 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.